Enclomiphene Citrate Cost in California 2026

What Is Enclomiphene Citrate and Why Does the Price Vary So Much?

Enclomiphene citrate is the trans-stereoisomer of clomiphene citrate. It acts as a selective estrogen receptor modulator at the hypothalamus, blocking negative feedback and thereby raising endogenous luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn stimulates testicular testosterone production [1]. Because it preserves the hypothalamic-pituitary-gonadal axis rather than bypassing it, sperm counts typically remain intact, a quality that makes it attractive for men with secondary hypogonadism who want to maintain fertility [2].

Price variation in California comes down to three factors: whether you fill a branded versus compounded product, which pharmacy you use, and whether your insurance covers it. The branded product Androxal (NDA 022461) was approved by the FDA for secondary hypogonadism in men but has had limited commercial availability in retail chains [3]. Most California patients currently access enclomiphene through 503A compounding pharmacies, which may charge roughly $90 per month for a 25 mg capsule formulation. Retail pharmacies that do carry a manufactured product typically price it between $120 and $250 per month depending on strength and quantity.

A 2016 randomized controlled trial by Kim et al. (BJU Int, N=144) found that enclomiphene 12.5 mg and 25 mg daily normalized serum testosterone in men with secondary hypogonadism while maintaining sperm concentrations significantly above the levels seen with topical testosterone gel [2]. That fertility-sparing profile is a major reason prescribers in California and nationally have increased utilization even before generic competition reduced prices.

The California Board of Pharmacy licenses 503A compounding pharmacies under California Business and Professions Code Section 4127, with additional federal oversight under the Drug Quality and Security Act. A 503A pharmacy may prepare enclomiphene for an individual patient with a valid prescription, keeping costs lower than a nationally distributed branded product because the pharmacy does not carry the same regulatory and distribution overhead [4].

Cash-Pay Prices at California Retail and Compounding Pharmacies

Cash-pay prices differ substantially between large retail chains and compounding pharmacies in California. At major chains such as CVS, Walgreens, and Rite Aid, a 30-day supply of enclomiphene citrate 25 mg can cost $150 to $250 without insurance as of early 2026. Smaller independent pharmacies may come in at $120 to $160. GoodRx and similar discount card programs sometimes reduce the retail price to the $100 to $140 range depending on the specific ZIP code and pharmacy, though discount cards cannot be combined with insurance benefits [5].

Compounding pharmacies licensed by the California Board of Pharmacy as 503A facilities generally charge around $90 per month for enclomiphene citrate 25 mg capsules. Some pharmacies offer a lower rate of $75 per month for a 12.5 mg dose. Prices can vary by 15 to 20 percent across California's major metro areas, with San Francisco and Los Angeles sometimes running slightly higher than Sacramento or Fresno due to overhead differences [6].

Patients who obtain enclomiphene through a telehealth platform that has an affiliated pharmacy may see bundled pricing. A telehealth consultation plus a three-month supply of compounded enclomiphene is sometimes offered in the $250 to $350 range total, which averages out to under $100 per month for the medication itself. Patients should confirm that the compounding pharmacy used by any telehealth service holds a current California Board of Pharmacy license, which can be verified at the board's online license lookup portal [4].

The table below summarizes the main price categories:

| Source | Approximate Monthly Cost (25 mg daily) | |---|---| | Retail pharmacy, no insurance | $150, $250 | | Retail pharmacy, GoodRx card | $100, $140 | | Licensed 503A compounding pharmacy | $75, $90 | | Telehealth platform (bundled) | ~$85, $100 (medication only) | | Medi-Cal (approved PA) | $0, $3 copay |

Does Medi-Cal Cover Enclomiphene Citrate in California?

Medi-Cal, California's Medicaid program, covers enclomiphene citrate for secondary hypogonadism with a prior authorization on file. The drug is used off-label for this indication because the FDA approval through NDA 022461 was for a specific clinical context, and Medi-Cal's Drug Utilization Review criteria mirror the clinical evidence rather than strictly limiting coverage to labeled indications [3]. Approval requires documentation of a low morning serum testosterone (generally below 300 ng/dL on two separate draws), an LH level that is low or inappropriately normal, and a diagnosis code consistent with hypogonadotropic hypogonadism [7].

The DHCS (California Department of Health Care Services) publishes its prior authorization criteria online. Prescribers typically submit a PA form with the patient's testosterone levels, LH, FSH, a brief history ruling out primary hypogonadism, and a note on fertility intent if relevant. Approval turnaround under standard processing is three to five business days; urgent requests may be processed in 24 to 72 hours [7].

Once approved, Medi-Cal beneficiaries in full-scope Medi-Cal pay a nominal copay of $1 to $3 per prescription. Beneficiaries enrolled in a Medi-Cal managed care plan should check their specific plan's formulary because some plans process the PA internally rather than through DHCS directly. Major Medi-Cal managed care plans in California include Health Net, Molina, and LA Care [8].

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism states: "We recommend confirming the diagnosis by repeating the measurement of morning total testosterone and, if low, measuring LH and FSH to determine whether hypogonadism is primary or secondary" [9]. This documentation framework is exactly what Medi-Cal reviewers expect to see in a PA submission for enclomiphene.

Commercial Insurance Coverage and Prior Authorization in California

Most commercial insurance plans operating in California, including Anthem Blue Cross, Blue Shield of California, Kaiser Permanente, UnitedHealthcare, and Aetna, classify enclomiphene citrate as a specialty or non-preferred brand that requires prior authorization. The clinical criteria generally mirror what Medi-Cal uses: two low morning testosterone values, documented LH and FSH, and a secondary hypogonadism diagnosis [10].

Kaiser Permanente Northern and Southern California plans evaluate enclomiphene on a case-by-case basis under their pharmacy and therapeutics committee criteria. Blue Shield of California's PA form asks specifically whether the prescriber has documented that topical testosterone is not appropriate, typically because the patient wants to preserve fertility. Providing that documentation upfront reduces the likelihood of an initial denial [10].

If a plan denies the PA, California law under Insurance Code Section 10169 gives patients the right to an independent medical review (IMR) through the Department of Managed Health Care. The IMR process has overturned denials in cases where the clinical evidence clearly supports the prescribed therapy. Filing an IMR is free for California-insured patients [11].

A practical tip: prescribers should include the specific serum testosterone value, the collection time (morning, fasting), the LH and FSH results, and a sentence explaining why testosterone replacement therapy is not preferred for this patient. That sentence alone, when it mentions fertility preservation or HPG axis integrity, is often sufficient to meet the medical necessity threshold [9].

Is Compounded Enclomiphene Citrate Legal in California?

Compounded enclomiphene citrate is legal in California when prepared by a 503A pharmacy operating under a valid patient-specific prescription. The California Board of Pharmacy licenses these facilities and inspects them against USP 795 (non-sterile compounding) standards. Federal law under the Federal Food, Drug, and Cosmetic Act Section 503A permits compounding for individual patients when a licensed practitioner issues a valid prescription and the pharmacy meets quality standards [4].

The FDA does not currently list enclomiphene on its list of drugs that may not be compounded (the "negative list" or Category 2 list under Section 503B), which means 503A pharmacies may compound it for individual patients. The agency has, however, noted that compounded versions of approved drugs may raise questions about clinical equivalence; patients should be aware that compounded enclomiphene has not been tested for bioequivalence against the branded product in an FDA-reviewed study [3].

California's State Board of Pharmacy maintains a public license database where patients and prescribers can verify that a given pharmacy holds an active 503A license. Any pharmacy filling enclomiphene capsules without a current California license is operating outside the law, regardless of what a telehealth platform's website states. Patients who receive medication that appears to have been shipped from an unlicensed out-of-state facility should report this to the Board at www.pharmacy.ca.gov [4].

503B outsourcing facilities, by contrast, produce larger batches without patient-specific prescriptions and are federally registered with the FDA. A 503B facility may supply enclomiphene to a California clinic or prescriber for office use, which is a different legal pathway than a 503A pharmacy filling an individual Rx. Both are lawful; the distinction matters mainly for how the pharmacy operates, not for patient safety [12].

Telehealth Prescribing of Enclomiphene Citrate in California

California law permits telehealth prescribing of enclomiphene citrate. Under Business and Professions Code Section 2290.5, a valid patient-provider relationship can be established via synchronous video or telephone visit, and a Schedule V or non-scheduled prescription may then be issued electronically [13]. Enclomiphene citrate is not a controlled substance, so there are no DEA-related barriers specific to telehealth prescribing.

A prescriber using telehealth must still meet the same standard of care as an in-person visit. For enclomiphene, that means reviewing recent lab work, including serum testosterone (morning draw), LH, FSH, a complete metabolic panel, and ideally a semen analysis if fertility is a concern. The Endocrine Society guideline specifies that "biochemical diagnosis requires an unequivocally low serum testosterone concentration" confirmed on at least two occasions [9]. Telehealth prescribers who skip confirmatory labs expose themselves to licensing risk and may not meet the PA documentation threshold if the patient needs insurance coverage [7].

HealthRX physicians conducting telehealth visits for enclomiphene follow a standardized lab review protocol before any prescription is issued. Patients submit labs through the platform; the prescriber reviews testosterone, LH, FSH, hematocrit, and PSA (if age 40 or older) before the video visit. This sequence typically takes three to five business days from lab draw to prescription [9].

Several California-licensed telehealth platforms now offer enclomiphene prescribing, including HealthRX, Maximus, and others. Costs vary: some platforms charge a monthly membership fee of $30 to $75 on top of medication costs, while others include the consult fee in the medication price. Patients should ask whether the platform's affiliated pharmacy is California-licensed and whether the platform will assist with insurance prior authorization if the patient has commercial coverage [13].

Discount Programs and Savings Strategies in California

Several cost-reduction pathways exist for California patients paying out of pocket for enclomiphene citrate. GoodRx, RxSaver, and Blink Health aggregate pharmacy discounts and can reduce retail prices to $100 to $140 per month at participating California pharmacies [5]. These programs work by negotiating pre-negotiated rates with pharmacy benefit managers; the savings card is presented at the pharmacy counter and the discount applies at point of sale. Discount cards cannot be used simultaneously with Medi-Cal or commercial insurance.

Manufacturer patient assistance programs are limited for enclomiphene because the primary branded product (Androxal) has had restricted commercial availability. Patients should check the manufacturer's website directly for any updated assistance programs, as availability changes [3].

Compounding pharmacy subscription models offer another savings pathway. Some California 503A compounding pharmacies offer a 90-day supply of enclomiphene citrate 25 mg for $240 to $255, which reduces the per-month cost to $80 to $85. Auto-refill enrollment sometimes yields an additional 5 to 10 percent discount [6].

For patients enrolled in a Covered California plan (the state's ACA marketplace), enclomiphene may be covered under the Essential Health Benefits framework if a physician documents medical necessity. Silver-tier and gold-tier plans in California are more likely to have reasonable specialty drug cost-sharing than bronze-tier plans, which often have higher deductibles that must be met before drug coverage kicks in [11].

The California Rx program (CARx), a state-run discount program, provides additional savings at participating pharmacies for residents who do not have other drug coverage. Discounts vary by drug and pharmacy but may reduce costs by 10 to 35 percent compared to full retail price [8].

Monitoring Costs: Labs and Follow-Up

Medication cost is only part of the total expense. Patients starting enclomiphene in California should budget for follow-up laboratory testing at roughly 4 to 6 weeks after initiation, repeating testosterone, LH, FSH, estradiol, and hematocrit. Kim et al. (BJU Int 2016, N=144) showed that testosterone normalization was detectable at 3 months in responders, making a 3-month lab draw a useful checkpoint [2]. Lab costs depend on insurance status; a standard hormone panel at Quest Diagnostics or LabCorp in California runs $80 to $180 cash-pay, though many insurers cover monitoring labs at low or no cost once the diagnosis is established [14].

The Endocrine Society recommends monitoring hematocrit in men on testosterone-stimulating therapies because even endogenous testosterone elevation can raise red cell mass. An annual hematocrit above 54 percent is a threshold that warrants dose adjustment or temporary discontinuation [9]. Patients who are also receiving erythropoiesis-stimulating agents or who have sleep apnea should be monitored more frequently [15].

PSA monitoring is appropriate for men age 40 and older who start enclomiphene, mirroring the standard used for exogenous testosterone therapy. A PSA rise of more than 1.4 ng/mL over any 12-month period on therapy warrants urology referral [9]. Adding one PSA draw per year at $30 to $60 cash-pay is a reasonable budget assumption [14].

How Enclomiphene Compares to Clomiphene and TRT on Cost

Clomiphene citrate (generic clomiphene, 25 to 50 mg every other day or daily) is available at retail pharmacies for $15 to $40 per month in California, making it substantially cheaper than enclomiphene [5]. The cost difference reflects the fact that clomiphene's zuclomiphene isomer raises estradiol more than enclomiphene does, which some patients tolerate poorly; enclomiphene's cleaner receptor profile carries a price premium [1].

Testosterone cypionate injectable TRT, by contrast, costs roughly $30 to $60 per month for the drug itself, though it requires regular injections and can suppress sperm production. Topical testosterone gel (e.g., AndroGel 1.62%) runs $200 to $400 per month without insurance, making enclomiphene's compounded price of $90 per month favorable for patients who want to preserve fertility and avoid daily skin application [16].

A head-to-head cost-effectiveness analysis from a managed care perspective would need to weigh drug cost against the downstream costs of fertility treatment if TRT suppresses spermatogenesis. For a man planning conception within 12 to 24 months, enclomiphene's $90 per month compounded price may save thousands of dollars in assisted reproduction costs compared to reversing TRT-induced azoospermia, which can take 6 to 18 months after discontinuation [2].

Practical Steps to Get Enclomiphene in California at the Lowest Cost

Start with labs. A morning testosterone draw (collected before 10 a.m.) plus LH, FSH, and estradiol provides the diagnostic foundation and the documentation needed for any insurance PA [9]. Quest Diagnostics and LabCorp both operate walk-in sites throughout California; fasting is not required for the hormone panel.

Book a telehealth visit with a California-licensed prescriber who has reviewed your labs. During the visit, discuss whether 12.5 mg or 25 mg is appropriate given your testosterone level and fertility goals. If you have Medi-Cal, ask the prescriber to submit a PA at the time of prescribing. If you have commercial insurance, ask whether the platform provides PA support [13].

Request that the prescription be sent to a California-licensed 503A compounding pharmacy if cost is a primary concern. Confirm the pharmacy's license number on the California Board of Pharmacy website before the prescription is transferred [4].

If you are paying cash, present a GoodRx or RxSaver card at the retail pharmacy counter, or enroll in the compounding pharmacy's 90-day subscription at checkout. The 90-day supply at a compounding pharmacy is typically $240 to $255, compared to $270 at a retail pharmacy with a discount card, saving $15 to $30 per quarter [5].

Schedule a follow-up lab draw at 6 weeks to confirm testosterone response. Adjust dose only under physician supervision. Most patients see testosterone reach the mid-normal range (400 to 600 ng/dL) within 6 to 12 weeks on 25 mg daily [2].